{
    "root": "34759de3-8b17-9ab2-e063-6394a90a6a3e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Naproxen",
    "value": "20250506",
    "ingredients": [
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18012"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "NAPROXEN",
            "code": "57Y76R9ATQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7476"
        }
    ],
    "indications": {
        "text": "naproxen oral suspension indicated : relief signs symptoms : \u2022 rheumatoid arthritis \u2022 osteoarthritis \u2022 ankylosing spondylitis \u2022 polyarticular juvenile idiopathic arthritis \u2022 tendonitis \u2022 bursitis \u2022 acute gout management : \u2022 pain \u2022 primary dysmenorrhea",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "bursitis (DOID:2965)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2965"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "lowest effective dose shortest duration consistent individual patient treatment goals . ( 2 ) rheumatoid arthritis , osteoarthritis , ankylosing spondylitis naproxen oral suspension 250 mg ( 10 ml ) 375 mg ( 15 ml ) 500 mg ( 20 ml ) twice daily twice daily twice daily dose may adjusted depending response patient . patients tolerate lower doses well , dose may increased naproxen 1500 mg/day 6 months . polyarticular juvenile idiopathic arthritis recommended total daily dose naproxen approximately 10 mg/kg given 2 divided doses . following table may used guide dosing naproxen suspension : patient \u2019 weight dose administered 13 kg ( 29 lb ) 62.5 mg twice daily 2.5 ml ( 1/2 tsp ) twice daily 25 kg ( 55 lb ) 125 mg twice daily 5.0 ml ( 1 tsp ) twice daily 38 kg ( 84 lb ) 187.5 mg twice daily 7.5 ml ( 1 1/2 tsp ) twice daily management pain , primary dysmenorrhea , acute tendonitis bursitis recommended starting dose naproxen oral suspension 500 mg ( 20 ml ) , followed 250 mg ( 10 ml ) every 6 8 hours required . acute gout recommended starting dose 750 mg ( 30 ml ) naproxen oral suspension followed 250 mg ( 10 ml ) every 8 hours attack subsided .",
        "doid_entities": [
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            },
            {
                "text": "juvenile idiopathic arthritis (DOID:676)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_676"
            },
            {
                "text": "bursitis (DOID:2965)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2965"
            },
            {
                "text": "gout (DOID:13189)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13189"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute tendonitis bursitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            }
        ]
    },
    "warningsAndPrecautions": "naproxen oral suspension , usp : 125 mg/5 ml ( contains 39 mg sodium ) available light orange-colored oral suspension 1 pint ( 500 ml ) light-resistant bottles . supplied follows : one 500 ml bottle child-resistant closure : ndc 31722-682-05 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . avoid excessive heat 40\u00b0c ( 104\u00b0f ) . dispense light-resistant containers . shake gently .",
    "adverseReactions": "naproxen oral suspension contraindicated following patients : known hypersensitivity ( e.g . , anaphylactic serious skin ) naproxen components product [ ( 5.7 , 5.9 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.7 , 5.8 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.1 ) ]",
    "indications_original": "Naproxen oral suspension is indicated for: \n    the relief of the signs and symptoms of: \n    \u2022 rheumatoid arthritis \n    \u2022 osteoarthritis \n    \u2022 ankylosing spondylitis \n    \u2022 polyarticular juvenile idiopathic arthritis \n    \u2022 tendonitis \n    \u2022 bursitis \n    \u2022 acute gout \n    the management of: \n    \u2022 pain \n    \u2022 primary dysmenorrhea",
    "contraindications_original": "Use the lowest effective dose for shortest duration consistent with individual patient treatment goals. ( 2 ) Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis Naproxen oral suspension 250 mg (10 mL) or 375 mg (15 mL) or 500 mg (20 mL) twice daily twice daily twice daily The dose may be adjusted up or down depending on the clinical response of the patient. In patients who tolerate lower doses well, the dose may be increased to naproxen 1500 mg/day for up to 6 months. Polyarticular Juvenile Idiopathic Arthritis Recommended total daily dose of naproxen is approximately 10 mg/kg given in 2 divided doses. The following table may be used as a guide for dosing of naproxen suspension: Patient\u2019s Weight Dose Administered as 13 kg (29 lb) 62.5 mg twice daily 2.5 mL (1/2 tsp) twice daily 25 kg (55 lb) 125 mg twice daily 5.0 mL (1 tsp) twice daily 38 kg (84 lb) 187.5 mg twice daily 7.5 mL (1 1/2 tsp) twice daily Management of Pain, Primary Dysmenorrhea, and Acute Tendonitis and Bursitis The recommended starting dose of naproxen oral suspension is 500 mg (20 mL), followed by 250 mg (10 mL) every 6 to 8 hours as required. Acute Gout The recommended starting dose is 750 mg (30 mL) of naproxen oral suspension followed by 250 mg (10 mL) every 8 hours until the attack has subsided.",
    "warningsAndPrecautions_original": "Naproxen oral suspension, USP: 125 mg/5 mL (contains 39 mg sodium) is available as a light orange-colored oral suspension in 1 pint (500 mL) light-resistant bottles. It is supplied as follows: \n    One 500 mL bottle with child-resistant closure:\u00a0 NDC 31722-682-05 \n  \n                     Storage\n                       Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. Avoid excessive heat above 40\u00b0C (104\u00b0F). Dispense in light-resistant containers. Shake gently before use.",
    "adverseReactions_original": "Naproxen oral suspension is contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product\n  \n   [see Warnings and Precautions (\n   \n    5.7,\n   \n    5.9)]\n  \n   \n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients\n  \n   [see Warnings and Precautions (\n   \n    5.7,\n   \n    5.8)]\u00a0\n  \n   \n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery\n  \n   [see Warnings and Precautions (\n   \n    5.1)]",
    "drug": [
        {
            "name": "Naproxen",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7476"
        }
    ]
}